Physician profile
Steven Baumgarten
NPI 1528038114
$8,744.68
in general payments reported to CMS, 2019-2025
40 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what 83% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $649 · 2021: $848 · 2022: $1,838 · 2023: $1,396 · 2024: $1,573 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,449 · Education: $18.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,449.18 |
| Education | $18.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,116.33 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $1,986.65 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $512.47 | 2019-2024 | Yupelri |
| Genzyme Corporation | $491.31 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.77 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $343.99 | 2019-2025 | Dupixent |
| Inari Medical, INC. | $331.87 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $327.18 | 2019-2024 | Opsumit, Uptravi |
| United Therapeutics Corporation | $234.59 | 2019-2025 | Tyvaso, Tyvaso |
| Harmony Biosciences LLC | $217.52 | 2021-2025 | Wakix |
| Insmed, INC. | $164.08 | 2019-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $161.02 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Axsome Therapeutics, INC. | $156.38 | 2022-2025 | Sunosi |
| Novartis Pharmaceuticals Corporation | $125.56 | 2019-2022 | |
| Verona Pharma, INC. | $110.44 | 2025 | Ohtuvayre |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $109.60 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Grifols USA, LLC | $101.76 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $92.73 | 2019-2020 | |
| Amgen INC. | $92.59 | 2022-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $91.09 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $88.06 | 2022-2023 | Airduo Digihaler |
| Merck Sharp & Dohme LLC | $84.57 | 2022-2023 | Belsomra |
| Electromed, INC. | $46.29 | 2019-2025 | Smartvest |
| Paratek Pharmaceuticals, INC. | $39.58 | 2019-2024 | Nuzyra |
| Inspire Medical Systems, INC. | $38.08 | 2024 | Inspire |
| Advanced Respiratory, INC | $36.36 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.29 | 2023 | |
| Exact Sciences Corporation | $30.09 | 2024 | Cologuard Collection Kit |
| Pulmonx Corporation | $29.94 | 2022-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Pfizer INC. | $29.45 | 2019-2023 | |
| Ani Pharmaceuticals, INC. | $23.62 | 2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $20.24 | 2025 | Aralast |
| Azurity Pharmaceuticals, INC. | $18.98 | 2025 | Horizant |
| Resmed Corp | $18.30 | 2025 | |
| Lilly USA, LLC | $17.81 | 2025 | Zepbound |
| Pharming Healthcare, INC. | $15.24 | 2023 | Ruconest |
| Phadia US INC. | $15.05 | 2025 | Immunocap |
| Viatris Specialty LLC | $14.17 | 2025 | Yupelri |
| Mallinckrodt Enterprises LLC | $13.02 | 2019 | |
| Abbvie INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Baumgarten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.